Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

Leukemia

Volumn 16, Issue 10, 2002, Pages 2027-2036

  Tse, K F ^a   Allebach, J ^a   Levis, M ^a   Smith, B D ^a   Bohmer, F D ^b   Small, D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

AML; FLT3 ITD; Tyrosine kinase inhibitor

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; FLT3 LIGAND; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; STAT5B PROTEIN; TYRPHOSTIN; UNCLASSIFIED DRUG; VAV PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER PATIENT; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; IC 50; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INHIBITION KINETICS; ISOLATION PROCEDURE; PRIORITY JOURNAL; PROTEIN BLOTTING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TANDEM REPEAT;

EID: 0036799356     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402674     Document Type: Article

References (54)

1. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-1152.
2. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog 1993; 4: 595-613.
3. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak M, Gewirtz AM, Civin C. STK-1, the human homolog of Flk2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Nat Acad Sci USA 1994; 91: 459-463.
4. Gotze KS, Ramirez M, Tabor K, Small D, Matthews W, Civin CI. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood 1998; 91: 1947-1958.
5. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-648.
6. Zhang S, Broxmeyer H. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and pi3 kinase. Biochem Biophys Res Commun 2000; 277: 195-199.
7. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ, Broxmeyer HE. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000; 192: 719-728.
8. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem 1998; 273: 14962-14967.
9. Tse KTF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766-1776.
10. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SID. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995; 23: 1121-1129.
11. Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Bennett M, Kumar V. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J Immunol 1999; 163: 2648-2656.
12. Arrighi JF, Hauser C, Chapuis B, Zubler RH, Kindler V. Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(-)CD]4(-) and a CD34(-)CD14(+) dendritic cell precursor. Blood 1999; 93: 2244-2252.
13. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, Witte L, Borowitz MJ, Civin CI, Small D. Expression of the hematopoietic growth factor receptor FLT3 (STK-I/Flk2) in human leukemias. Blood 1996; 87: 1089-1096.
14. Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, Arnoulet C. Chabannon C, Kanz L, Hannum C, Birnbaum D. Human FLT3/FLK2 redeptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10: 238-248.
15. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996; 88: 3987-3997.
16. Brasel K, Escobar S, Anderberg R, de Vries P, Gruss HJ, Lyman SD. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 1995; 9: 1212-1218.
17. Solanilla A, Crosset C, Lemercier C, Dupouy M, Mahon FX, Schweitzer K, Rciffers J, Weksler B, Ripoche J. Expression of Flt3-ligand by the endothelial cell. Leukemia 2000; 14: 153-162.
18. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoc T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-631.
19. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
20. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-1609.
21. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
22. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
23. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, Kato K, Kojima S, Matsuyama T. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999; 33: 525-529.
24. Meshinchi S, Woods WG, Stirewalt DL, Swectser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
25. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675-683.
26. Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, Watanabe A, Kikuta A, Tanaka A, Asami K, Sekine I, Mugishima H, Nishimura Y, Koizumi S, Horikoshi Y, Mimaya J, Ohta S, Nishikawa K, Iwai A, Shimokawa T, Nakayama M, Kawakami K, Gushiken T, Hyakuna N, Fujimoto T. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 1999; 13: 38-43.
27. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
28. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-195.
29. Abu-Duhier FM, Goodevc AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983-988.
30. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, Buchner T, Kienast J, Kanakura Y, Berdel WE, Serve H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-3914.
31. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989; 32: 2344-2352.
32. Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer F. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indolc tyrphostins. J Med Chem 1996; 39: 2170-2177.
33. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 1001-1010.
34. Levis M, Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885-887.
35. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin C, Waltenberger J, Bohmer F, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse cis-transformation. Cancer Res 1994; 54: 6106-6114.
36. Bustelo XR. The VAV family of signal transduction molecules. Crit Rev Oncog 1996; 7: 65-88.
37. Hara T, Miyajima A. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells 1996; 14: 605-618.
38. Darnell JE, Kerr IM, Stark G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1420.
39. Fukazawa T, Reedquist K, Trub T, Soltoff S, Panchamoorthy G, Druker B, Cantley L, Shoelson S, Band H. The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase. J Biol Chem 1995; 270: 19141-19150.
40. Donovan J, Wange R, Langdon W, Samelson L. The protein product of the c-cbl protooncogene is the 120-kDatyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigenreceptor. J Biol Chem 1994; 269: 22921-22924.
41. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci USA 1989; 86: 1168-1172.
42. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998; 12: 301-310.
43. Barber DL, Mason JM, Fukazawa T, Rcedquist KA, Druker BJ, Band H, D'Andrea AD. Erythropoietin and interieukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood 1997; 89: 3166-3174.
44. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, Miyata T, Itoh S, Narimatsu M, Maeda H, Fukada T, Itoh M, Okano H, Hibi M, Hirano T. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 2000; 12: 95-105.
45. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 2000; 275: 12848-12856.
46. Zhang S, Broxmeyer HE. p85 subunit of P13 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochem Biophys Res Commun 1999; 254: 440-445.
47. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333-1337.
48. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
49. Druker B, Sawyers C, Kantarjian H, Resta D, Reese S, Ford J, Capdeville R, Talpaz M. Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
50. Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Lydon N, Kantarjian H, Capdeville R, Ohno-jones S, Sawyers C. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
51. Druker B, Ttamura S, Buchdunger E, Ohno S, Segal G, Fanning S. Effects of a selective inhibitor of the AN tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
52. Kovalenko M, Ronnstrand L, Heldin C-H, Loubtchenkov M, Gazit A, Levitzki A, Bohmer F. Phosphorylation site-specific inhibition of platelet-derived growth factor B-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 1997; 36: 6260-6269.
53. Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q Morris SW, Skorski T. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 2001; 61: 6517-6523.
54. Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel A, Lerner E, Smithgall T, Grandis J. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 2002; 21: 2846-2853.